Primary failure of arteriovenous fistulae in auto-immune disease

Kidney and Blood Pressure Research

Volumn 26, Issue 5-6, 2003, Pages 362-367

  Baumann, Marcus ^a   Niebel, Wolfgang ^a   Kribben, Andreas ^a   Philipp, Thomas ^a   Heemann, Uwe ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chronic haemodialysis, primary arteriovenous fistula failure; Primary venous access failure; Thrombophilic risk; Vascular access

Indexed keywords

FIBRINOGEN;

ADOLESCENT; ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; EVALUATION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; CATHETERS, INDWELLING; CHILD; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VASCULITIS;

EID: 0345689564     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073943     Document Type: Article

References (24)

1. Brescia MJ, Cimino JE, Appel K, Hurwich BJ: Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966;275:1089-1092.
2. Bay WH, Henry ML, Lazarus JM, Lew NL, Ling J, Lowrie EG: Predicting hemodialysis access failure with color flow Doppler ultrasound. Am J Nephrol 1998;18:296-304.
3. Fan PY, Schwab SJ: Vascular access: Concepts for the 1990s. J Am Soc Nephrol 1992;3:1-11.
4. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL: Vascular access for hemodialysis: Patency rates and results of revision. Ann Surg 1985;202:235-239.
5. Levin N, Eknoyan G, Pipp M, Steinberg E: National Kidney Foundation: Dialysis Outcome Quality Initiative - Development of methodology for clinical practice guidelines. Nephrol Dial Transplant 1997;12:2060-2063.
6. Windus DW, Jendrisak MD, Delmez JA: Prosthetic fistula survival and complications in hemodialysis patients: Effects of diabetes and age. Am J Kidney Dis 1992;19:448-452.
7. Woods JD, Turenne MN, Strawderman RL, Young EW, Hirth RA, Port FK, Held PJ: Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis 1997;30:50-57.
8. Culp K, Flanigan M, Taylor L, Rothstein M: Vascular access thrombosis in new hemodialysis patients. Am J Kidney Dis 1995;26:341-346.
9. Fodinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Hörl WH, Sunder-Plassmann G: Resistance to activated protein C (APC): Mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant 1996;11: 668-672.
10. Wuthrich RP: Factor V Leiden mutation: Potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens 2001;10:409-414.
11. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 1994;45:1477-1483.
12. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C: Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;40:611-622.
13. Cante P, Bottet P, Ryckelynck JP, Le Roch B, Levaltier B, Lobbedez T, Bensadoun H: Distal vascular access for chronic hemodialysis in patients over 65 years of age: Surgical results. Prog Urol 1998;8:83-88.
14. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485.
15. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino RB Sr: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102:1634-1638.
16. Sherman DG, Levy DE: Outcomes of ancrod in acute ischemic stroke. JAMA 2000;284:1926-1927.
17. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:640-644.
18. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
19. Koike T: Antiphospholipid antibodies in arterial thrombosis. Ann Med 2000;32(suppl 1): 27-31.
20. Brenner B, Tavori S, Lerner M, Tatarsky I, Lorber M: Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders. Isr J Med Sci 1992;28:9-15.
21. Castellino G, La Corte R, Santilli D, Trotta F: Wegener's granulomatosis associated with anti-phospholipid syndrome. Lupus 2000;9:717-720.
22. Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA: Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: Evidence for a prothrombotic state. Blood 1993; 81:2958-2963.
23. Konner K: Increasing the proportion of diabetics with AV fistulas. Semin Dial 2001;14:1-4.
24. Obialo CI, Robinson T, Brathwaite M: Hemodialysis vascular access: Variable thrombus-free survival in three subpopulations of black patients. Am J Kidney Dis 1998;31:250-256.